Lilly Doubles Down On Novel Pain Drugs With Confo Therapeutics Deal

Adds To Three Non-Opioid Candidates In Pipeline

 
• By Andrew McConaghie
  
Eli Lilly logo sign atop Lilly Biotechnology Center
The deal means that Lilly now has four candidates in development against pain. • Source: Michael Vi / Shutterstock.com
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip